Imatinib Aenorasis

Imatinib, the active ingredient in Imatinib Aenorasis, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors in adult patients.

GNH USA supplies Imatinib Aenorasis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The company ensures batch‑to‑batch consistency and supports regulatory compliance for its partners.

Imatinib is a tyrosine kinase inhibitor used primarily in hematologic and gastrointestinal malignancies that involve BCR‑ABL or KIT signaling.

- Chronic myeloid leukemia (CML): achieves inhibition of leukemic cell proliferation and disease control. - Gastrointestinal stromal tumor (GIST): achieves reduction of tumor growth and disease stabilization. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides disease remission in eligible patients.

Adverse reactions may occur with imatinib therapy.

Common Side Effects: - Nausea - Fluid retention or peripheral edema - Muscle cramps or spasms - Fatigue

Serious or Rare Side Effects: - Severe neutropenia or other cytopenias - Hepatotoxicity with elevated transaminases - Cardiac failure or reduced left‑ventricular ejection fraction

Patients receiving imatinib should be monitored for safety and efficacy.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check transaminases before and during therapy. - Evaluate cardiac status: watch for signs of heart failure. - Avoid use in patients with known hypersensitivity to imatinib. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Imatinib may interact with several concomitant medicines.

Major Interactions (Avoid): - Concomitant strong CYP3A4 inhibitors (e.g., ketoconazole) may increase imatinib exposure. - CYP3A4 inducers (e.g., rifampicin) may reduce imatinib efficacy. - Antacids containing aluminum or magnesium may decrease absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Cytarabine: potential additive myelosuppression. - Live vaccines: may be less effective; consider timing of vaccination.